The Kowa Pharmaceuticals receives untitled letters, over a youtube testimonial video posted by a patient, on claims over satin drug Livalo. The letters were issued by the U.S. Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP).

As of 2019, five untitled letters and two warning letters have been issued to the drugmakers by the OPDP. The letters were over the promotional materials for their products overall. The FDA further made a note that there could be serious risks in misrepresenting any cautious information surrounding the drug such as Livalo.